Insights - Arena Pharmaceuticals (ARNA) reported a surprising earnings beat and profit in its second quarter, with EPS of $0.03, $0.14 better than Wall Street analysts who called for a … Continue Reading
Read NowResearch - Orexigen Therapeutics (OREX) has again dipped below $5.50, which we find attractive 6 weeks ahead of the September 11 PDUFA decision for NB32 (Contrave, naltrexone/bupropion), … Continue Reading
Read NowInsights - KaloBios Pharmaceuticals (KBIO) slid 16% to $1.61 in after hours trading on the news that Sanofi Pasteur, the vaccines division of French pharma giant Sanofi, … Continue Reading
Read NowResearch - After the bell on Friday evening, AcelRx (ACRX) reported that the FDA has issued a Complete Response Letter (CRL) to the company’s new drug application for Zalviso (sufentanil … Continue Reading
Read NowInsights - The story of the week was Puma Biotechnology’s (PBYI) unexpected success in the phase 3 ExteNET trial, which sent the stock soaring 200% in after hours trading on Tuesday … Continue Reading
Read NowInsights - A second late-stage study of Incyte’s (INCY) Jakafi (ruxolitinib) in polycythemia vera (PV) failed on Wednesday, though the company says the study isn’t necessary for FDA approval. RELIEF was … Continue Reading
Read NowInsights - Biogen Idec (BIIB) trounced analyst estimates on Wednesday, a beat led by $700 million in Tecfidera sales during the quarter that topped consensus estimates for $561 million. Ex-U.S., the … Continue Reading
Read Now
